IBB

iShares Biotechnology ETF (IBB) | Rumor.io

iShares Biotechnology ETF

IBB

Attention (50-day avg)0.11%

Attention rank (50-day avg)#106

Bullish sentiment (50-day avg)82%

Price to earnings ratio26.2

Net assets11.8B

Expense ratio0%

Social

What share of all ETF conversation is about IBB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0.09% +0.03	0.07% -0.09	0.02% +0.01

Sep 2

IBB is setting up for another potential run, with a bull flag forming.
A large 9/2026 $158 put option in XBI is generating significant premium, worth $2.4 million.
The biotech sector, represented by IBB, may be poised for another increase.

Generated by AI

Sentiment

Of the messages about IBB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	71.43% +11.43	77.26% +4.09	77.66% -9.51	85.91% +12.65
Bearish	28.57% -11.43	22.74% -4.09	22.34% +9.51	14.09% -12.65

Bullish· Aug 19

The iShares Biotechnology ETF ($IBB) has broken out of a half-decade base, indicating a potentially significant upward trend.
The ETF has seen a 32.5% increase since late March and a 54% rise over the last year, outperforming the Nasdaq-100 ETF ($QQQ).
Biotech and pharmaceutical stocks, including $IBB, have reached all-time highs, clearing previous peaks and showing strong momentum.

Bearish· Jun 28

$IBB's recent price action has reached its profit targets, with the RSI indicator showing short-term overbought levels.
The RSI indicator is currently flashing short-term overbought signals, suggesting that the $IBB price may be due for a correction.
The $IBB price has become "a bit stretched" short-term, according to the RSI indicator, potentially indicating a need for profit-taking.

Generated by AI

Topics

Of the messages about IBB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Technical Analysis	100%	100%	100%	97.27%
Macro	0%	0%	0%	2.73%

Macro· Jul 15

Janet Yellen's comments on growth stock valuations caused a decline in the iShares Biotechnology ETF ($IBB) and the Global X Social Media ETF ($SOCL).
Yellen's speech was seen as a warning on overvalued stocks, with some biotechs in the $IBB ETF being particularly affected.
The market reaction to Yellen's comments was seen as irrational, with some traders selling their $IBB biotech stocks despite Yellen's reassurance on inflation.

Technical Analysis· Aug 19

The iShares Biotechnology ETF ($IBB) has broken out from a half-decade base, which is a significant development that may signal the start of a larger trend.
The ETF has seen significant gains this year, and some analysts are recommending it as a trade, citing the biotech and pharma sector's growing importance.
The ETF's breakout may be driven by the administration's nomination of a new FDA commissioner, who is expected to prioritize faster cures, clinical trial reforms, and lower drug prices.

Generated by AI

Community

Of the messages about IBB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	22.22%	90.51%	87.27%	78.68%
Newcomers	77.78%	9.49%	12.73%	21.32%

Regulars· Aug 21

The regulars are excited about the recent developments in biotechnology, specifically mentioning multiple preclinical experiments and collaborations that could lead to breakthroughs in oncology targets.
The mention of $IBB is primarily to highlight its relevance to the biotech sector, with the regulars focusing on the potential implications of these developments for the ETF.
The regulars are interpreting the Trump administration's actions as having enabled a biotech renaissance, with $IBB and $XBI being mentioned in the context of this sector's growth.

Newcomers· Jul 16

New investors are focusing on the current market performance of the iShares Biotechnology ETF ($IBB), noting its sector giving away money today.
Some newcomers are comparing the ETF's performance to other assets, mentioning that $MLTX had a disappointing day while $IBB had a similar performance.
Investors are also discussing the ETF's performance relative to the week's overall market activity, with some noting that its 5% gain is in line with the sector's performance.

Generated by AI

News

Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK | The Motley Fool

iShares offers lower fees and concentrated biotech exposure with stronger 1-year returns, while Simplify provides broader healthcare diversification and a higher dividend yield.

4d agofool.com

Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK

iShares offers lower fees and concentrated biotech exposure with stronger 1-year returns, while Simplify provides broader healthcare diversification and a higher dividend yield.

4d agoYahoo Finance

XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration | The Motley Fool

XLV offers exposure to the broader healthcare sector, while IBB targets biotech innovators. Here's how the two stack up on risk, returns, and diversification.

5d agoThe Motley Fool

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

1mo agoYahoo Finance

Biotech Is Booming, But These 2 Stocks Missed the Memo - Moderna (NASDAQ:MRNA), iShares Biotechnology ETF

1mo agoBenzinga

Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB? | The Motley Fool

IBB delivered 44% returns in one year but swung 40% lower at its worst. IXJ grew steadily with half the volatility and a 1.5% dividend yield.

2mo agoThe Motley Fool

Also Discussed

Investors talking about IBB also mention

#	Name	Attention
1	SPDR S&P Biotech ETFXBI	0.42%+0.08
2	ProShares Ultra Nasdaq BiotechnologyBIB	0%new
3	VanEck Biotech ETFBBH	0%new
4	Direxion Daily S&P Biotech Bull 3X SharesLABU	0.01%+0.01
5	Direxion Daily S&P Biotech Bear 3X SharesLABD	0.01%+0.01
6	Health Care Select Sector SPDR FundXLV	0.01%-0.01
7	iShares U.S. Transportation ETFIYT	0%0
8	Amgen Inc.AMGN	0.01%+0
9	Biogen IncBIIB	0%-0.01
10	Gilead Sciences, Inc.GILD	0%-0.04

iShares Biotechnology ETF

iShares Biotechnology ETF is an exchange-traded fund that provides broad exposure to U.S.-listed biotechnology companies. The fund is designed to track a biotechnology-focused index and typically holds a diversified basket of large, mid, and smaller biotechnology names, along with select life sciences tools and services companies that support drug discovery and research. Its portfolio includes firms involved in areas such as therapeutics, genetic medicine, diagnostics, and advanced research platforms. By concentrating on the biotechnology segment, iShares Biotechnology ETF serves as a sector-specific instrument for investors seeking access to one of the most research-intensive areas of the healthcare market. The fund is used by market participants as a way to gain diversified exposure to companies developing innovative medicines and scientific technologies within the healthcare industry.

Location

United States

Social

What share of all ETF conversation is about IBB?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% 0	0.09% +0.03	0.07% -0.09	0.02% +0.01

Sep 2

IBB is setting up for another potential run, with a bull flag forming.
A large 9/2026 $158 put option in XBI is generating significant premium, worth $2.4 million.
The biotech sector, represented by IBB, may be poised for another increase.

Generated by AI

Sentiment

Of the messages about IBB that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	71.43% +11.43	77.26% +4.09	77.66% -9.51	85.91% +12.65
Bearish	28.57% -11.43	22.74% -4.09	22.34% +9.51	14.09% -12.65

Bullish· Aug 19

The iShares Biotechnology ETF ($IBB) has broken out of a half-decade base, indicating a potentially significant upward trend.
The ETF has seen a 32.5% increase since late March and a 54% rise over the last year, outperforming the Nasdaq-100 ETF ($QQQ).
Biotech and pharmaceutical stocks, including $IBB, have reached all-time highs, clearing previous peaks and showing strong momentum.

Bearish· Jun 28

$IBB's recent price action has reached its profit targets, with the RSI indicator showing short-term overbought levels.
The RSI indicator is currently flashing short-term overbought signals, suggesting that the $IBB price may be due for a correction.
The $IBB price has become "a bit stretched" short-term, according to the RSI indicator, potentially indicating a need for profit-taking.

Generated by AI

Topics

Of the messages about IBB that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Technical Analysis	100%	100%	100%	97.27%
Macro	0%	0%	0%	2.73%

Macro· Jul 15

Janet Yellen's comments on growth stock valuations caused a decline in the iShares Biotechnology ETF ($IBB) and the Global X Social Media ETF ($SOCL).
Yellen's speech was seen as a warning on overvalued stocks, with some biotechs in the $IBB ETF being particularly affected.
The market reaction to Yellen's comments was seen as irrational, with some traders selling their $IBB biotech stocks despite Yellen's reassurance on inflation.

Technical Analysis· Aug 19

The iShares Biotechnology ETF ($IBB) has broken out from a half-decade base, which is a significant development that may signal the start of a larger trend.
The ETF has seen significant gains this year, and some analysts are recommending it as a trade, citing the biotech and pharma sector's growing importance.
The ETF's breakout may be driven by the administration's nomination of a new FDA commissioner, who is expected to prioritize faster cures, clinical trial reforms, and lower drug prices.

Generated by AI

Community

Of the messages about IBB, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	22.22%	90.51%	87.27%	78.68%
Newcomers	77.78%	9.49%	12.73%	21.32%

Regulars· Aug 21

The regulars are excited about the recent developments in biotechnology, specifically mentioning multiple preclinical experiments and collaborations that could lead to breakthroughs in oncology targets.
The mention of $IBB is primarily to highlight its relevance to the biotech sector, with the regulars focusing on the potential implications of these developments for the ETF.
The regulars are interpreting the Trump administration's actions as having enabled a biotech renaissance, with $IBB and $XBI being mentioned in the context of this sector's growth.

Newcomers· Jul 16

New investors are focusing on the current market performance of the iShares Biotechnology ETF ($IBB), noting its sector giving away money today.
Some newcomers are comparing the ETF's performance to other assets, mentioning that $MLTX had a disappointing day while $IBB had a similar performance.
Investors are also discussing the ETF's performance relative to the week's overall market activity, with some noting that its 5% gain is in line with the sector's performance.

Generated by AI

iShares Biotechnology ETF

Social

Sep 2

Bullish· Aug 19

Bearish· Jun 28

Macro· Jul 15

Technical Analysis· Aug 19

Regulars· Aug 21

Newcomers· Jul 16

Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK | The Motley Fool

Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK

XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration | The Motley Fool

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Biotech Is Booming, But These 2 Stocks Missed the Memo - Moderna (NASDAQ:MRNA), iShares Biotechnology ETF

Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB? | The Motley Fool

Also Discussed

iShares Biotechnology ETF

Company Information

Location

Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK | The Motley Fool

Better Healthcare ETF: iShares Biotechnology-Focused IBB vs. Simplify's Broad PINK

XLV vs IBB: How Healthcare Diversification Compares to Biotech Concentration | The Motley Fool

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Biotech Is Booming, But These 2 Stocks Missed the Memo - Moderna (NASDAQ:MRNA), iShares Biotechnology ETF

Which iShares Healthcare ETF Is the Better Buy: Diversified IXJ or Biotech-Focused IBB? | The Motley Fool

Also Discussed

Social

Sep 2

Bullish· Aug 19

Bearish· Jun 28

Macro· Jul 15

Technical Analysis· Aug 19

Regulars· Aug 21

Newcomers· Jul 16